Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-1
Release time:
2020-08-05
Stock Abbreviations: Jianfeng Group Stock Code: 600 668 Announcement No.: Pro 2013- 021
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Zhejiang Jianfeng Group Co., Ltd.
201 3 Corporate Bonds (Phase I)
Listing Announcement
Securities Abbreviation: 13 Peak 01
Securities Code: 122227
Total Issue: RMB 3 billion Yuan
Listing Time: 2013 7 2
Listing place: shanghai Stock Exchange
Sponsor (Lead Underwriter) / Listing Recommender
( Registered Address: hangzhou Hangzhou Hangzhou Hangzhou Road 1 )
2013 7 January
Section I Introduction
Important Tips
Zhejiang Jianfeng Group Co., Ltd. (the following is called "Jianfeng Group ", "Company" or "Issuer") Members of the Board of Directors have approved this Listing Announcement, guarantee that there are no false records, misleading Chen or material omissions, and assume individual and joint legal responsibility for its truthfulness, accuracy and completeness.
The approval of the Shanghai Stock Exchange (hereinafter referred to as the "SSE" ) for the listing of corporate bonds does not indicate a substantive judgment or guarantee of the investment value of the bonds or the return of investors. Investors who purchase bonds are responsible for the investment risks arising from changes in the company's operations and earnings. 117.
has been comprehensively evaluated byof United Credit Rating Co., Ltd. (hereinafter referred to as "United Rating " ). Jianfeng Group current corporate bonds Credit rating is AA + , and the main credit rating is AA ; Before the listing of bonds, the net assets of the issuer at the end of the latest period were ,164,643.81 .38 million yuan (total owner's equity of in the consolidated statement as of 2012 , 142# December , March 31 ) , and the asset-liability ratio of consolidated statement caliber was 40.74 (the asset-liability ratio of parent company caliber was 25.77 ); before the listing of the current bonds, the average annual distributable profit realized by the issuer in the last three fiscal years was 18,836.85 .56 million yuan (average of the net profit attributable to the owners of the parent company in the consolidated statements of 20 10 , 2011 and 201 2 #), expected not less than 1.5 times the one-year interest on this issue bonds. Section II Issuer Profile
1. Issuer Legal Name
Chinese Name: Zhejiang Jianfeng Group Co., Ltd.
English Name: ZHEJIANG JIANFENG GROUP CO.,LTD
2. Issuer Registered Address and Office Address
Registered Address: No. 88 193, Wujiang East Road, Jinhua City, Zhejiang Province
Office Address: No. 88 199, Wujiang East Road, Jinhua City, Zhejiang Province
3. Issuer Registered CapitalRegistered Capital: RMB 344,083,828.00 RMB
4. Issuer Legal Representative
Legal Representative: Jiang Xiaomeng
5. Issuer Basic Information
(I) Issuer Business Scope
Issuer's business scope is:cement, cement concrete, prefabricated components, common machinery, auxiliary materials, communication equipment, caulking materials, instruments and meters, paper bags manufacturing and sales, import and export business (see approval of the Foreign Trade Office for details), and industrial investment.
Main Business of (II) Issuers
According to "Guidelines for Industry Classification of Listed Companies (2012
Revision)" (CSRC Announcement [2012 ]
31), issuers belong to "Non-metallic Mineral Products Industry" and "Pharmaceutical Manufacturing Industry". The issuer's main business is cement manufacturing and sales, pharmaceutical manufacturing and sales, pharmaceutical commercial circulation. cement business is carried out in daye peak and Yunnan peak system, the issuer's holding subsidiaries. the issuer has been engaged in this business since was listed in 1993 , accounting for about 40% of the issuer's main business income. this business is mainly engaged in the production and sales of cement and cement clinker.
pharmaceutical business is carried out within the peak pharmaceutical system of the issuer's holding subsidiary, accounting for about 50% of the issuer's main business income . The business mainly covers two categories: pharmaceutical industry and pharmaceutical commerce. Company
2010, 2011 and 2012
, with operating income of132, .09 .63 million yuan, 164, .88 .65 million yuan and 164,909.55 .67 million yuan respectively, operating income stable growth ; the proportion of main business income to operating income is above 99% . The composition of the company's main business income in the past three years is as follows: units: ten thousand yuan
industry name
2012 degree |
2011 year |
2010 year |
amount |
|||
Proportion |
Amount |
Proportion |
Amount |
Proportion |
Cement Industry |
|
63,012.93 |
38.38% |
72,736.61 |
44.45% |
51,038.47 |
38.83% |
Pharmaceutical Industry |
82,785.43 |
50.42% |
76,543.88 |
46.77% |
65,262.72 |
49.66% |
other industries |
18,379.87 |
11.20% |
14,366.78 |
8.78% |
|||
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page